Reaction
Intestinal Operation reporting signals
As of the last recalculation, Intestinal Operation appears in 1,534 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is RISANKIZUMAB-RZAA (PRR 26.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Risankizumab-Rzaa | 146 | 26.7 | 26.7 |
| Infliximab | 242 | 17.7 | 17.7 |
| Upadacitinib | 79 | 13.8 | 13.8 |
| Infliximab-Dyyb | 27 | 12.7 | 12.8 |
| Ustekinumab | 79 | 11.0 | 11.0 |
| Vedolizumab | 65 | 10.6 | 10.7 |
| Pancrelipase | 27 | 9.6 | 9.7 |
| Rucaparib | 5 | 7.7 | 7.7 |
| Teduglutide | 7 | 7.1 | 7.1 |
| Ivacaftor | 3 | 5.1 | 5.1 |
| Esketamine Hydrochloride | 3 | 2.3 | 2.3 |